

Rb Vender

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3652270/publications.pdf>

Version: 2024-02-01

86
papers

2,352
citations

304743

22
h-index

223800

46
g-index

87
all docs

87
docs citations

87
times ranked

2248
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 319-320.	1.2	12
2	Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	7
3	Management of pediatric generalized pustular psoriasis using biologics: An evidence-based review. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 484-486.	1.2	4
4	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study. <i>JAAD International</i> , 2022, 6, 3-5.	2.2	2
5	Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 267-273.	1.2	4
6	Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS). <i>Dermatology and Therapy</i> , 2022, , 1.	3.0	0
7	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. <i>Dermatology and Therapy</i> , 2022, 12, 253-265.	3.0	2
8	Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2692-2694.	2.2	3
9	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. <i>Dermatology and Therapy</i> , 2022, 12, 1073-1089.	3.0	1
10	Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses.. <i>Skin Therapy Letter</i> , 2022, 27, 1-4.	0.3	0
11	Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 3S-23S.	1.2	6
12	Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 Can Be Divided Into Inflammatory and Vascular Patterns. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 169-176.	1.2	7
13	Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1169-1171.	1.2	11
14	A Review of Drug-Drug Interactions for Biologic Drugs Used in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 38-44.	1.2	5
15	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blind trial*. <i>British Journal of Dermatology</i> , 2021, 184, 1047-1058.	1.5	58
16	A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 298-302.	1.2	3
17	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	2.4	6
18	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , 2021, 397, 475-486.	13.7	136

#	ARTICLE	IF	CITATIONS
19	Psoriasis Prevalence and Severity by Expert Elicitation. <i>Dermatology and Therapy</i> , 2021, 11, 1053-1064.	3.0	28
20	Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e485-e487.	2.4	6
21	A Useful Clinical Tool for Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 120347542110291.	1.2	0
22	Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. <i>British Journal of Dermatology</i> , 2021, 185, 865-867.	1.5	5
23	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. <i>Frontiers in Medicine</i> , 2021, 8, 702776.	2.6	9
24	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358.	1.5	117
25	Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1212-1214.	1.2	19
26	The Incidence and Prevalence of Uveitis in Psoriasis: A Systematic Review and Meta-Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 601-607.	1.2	8
27	Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 418-419.	1.2	3
28	Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 3S-14S.	1.2	16
29	Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1813-1814.	1.2	5
30	Psoriasis, biologic therapy, and the pandemic of the 21st century. <i>Drugs in Context</i> , 2020, 9, 1-4.	2.2	7
31	Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. <i>JAAD International</i> , 2020, 1, 224-230.	2.2	3
32	The Role of IL-17 in Papulopustular Rosacea and Future Directions. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 635-641.	1.2	27
33	Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. <i>BioDrugs</i> , 2019, 33, 391-399.	4.6	30
34	Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 391-393.	1.2	10
35	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 282-288.	1.2	3
36	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18.	3.0	63

#	ARTICLE	IF	CITATIONS
37	Psoriasis patients'™ preference for an aerosol foam topical formulation. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e400-e401.	2.4	5
38	Survival of the fittest. British Journal of Dermatology, 2018, 178, 328-329.	1.5	1
39	Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatology and Therapy, 2018, 8, 17-32.	3.0	14
40	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery, 2018, 22, 78-83.	1.2	17
41	Canadian Patients'™ Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys. Journal of Cutaneous Medicine and Surgery, 2018, 22, 464-471.	1.2	4
42	AB0939'€œ...Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study. , 2018, , .		0
43	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. Journal of Rheumatology, 2017, 44, 519-534.	2.0	18
44	Acitretin Use in Dermatology. Journal of Cutaneous Medicine and Surgery, 2017, 21, 2S-12S.	1.2	27
45	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery, 2017, 21, 2S-40S.	1.2	9
46	An Open Letter to Health Canada. Journal of Cutaneous Medicine and Surgery, 2017, 21, 195-196.	1.2	0
47	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology, 2017, 177, 1495-1502.	1.5	48
48	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1'€œyear: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2017, 76, 60-69.e9.	1.2	258
49	Biosimilars for psoriasis: clinical studies to determine similarity. British Journal of Dermatology, 2017, 177, 23-33.	1.5	16
50	Review of Systemic Treatment Options for Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 31-39.	1.2	42
51	Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. British Journal of Dermatology, 2016, 174, 282-286.	1.5	38
52	Psoronychomycosis. Journal of Cutaneous Medicine and Surgery, 2016, 20, 279-280.	1.2	6
53	2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. Journal of Cutaneous Medicine and Surgery, 2016, 20, 375-431.	1.2	28
54	Acral Hemorrhagic Darier'™s Disease. Journal of Cutaneous Medicine and Surgery, 2016, 20, 478-480.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S12-S16.	0.1	26
56	Paradoxical, Cupping-Induced Localized Psoriasis: A Koebner Phenomenon. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 320-322.	1.2	18
57	Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 227-238.	1.2	24
58	Non-melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 216-226.	1.2	10
59	Think beyond the Skin. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 22-27.	1.2	31
60	Public Engagement with Dermatology Contents on Facebook. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 304-308.	1.2	12
61	Use of Facebook as a Tool for Knowledge Dissemination in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 341-344.	1.2	13
62	A Consensus on Acne Management Focused on Specific Patient Features. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 243-255.	1.2	6
63	Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 141-150.	1.2	267
64	Sulfa or Sulfur? Clearing Things up. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 79-81.	1.2	2
65	One-Year, Multicenter, Open-Label, Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 129-138.	1.2	8
66	Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 407-416.	1.2	9
67	Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 343-353.	2.1	14
68	Comparison of Dermatologists' and Nondermatologists' Diagnostic Accuracy for Malignant Melanoma. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 272-280.	1.2	7
69	Erythema ab igne caused by laptop computer gaming – a case report. <i>International Journal of Dermatology</i> , 2012, 51, 716-717.	1.0	7
70	Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 309-321.	1.2	11
71	Gourmet Clinical Pearls. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 63-64.	1.2	0
72	Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet. <i>Archives of Dermatology</i> , 2011, 147, 429.	1.4	96

#	ARTICLE	IF	CITATIONS
73	Occurrence of Plantar Pustular Psoriasis during Treatment with Infliximab. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 40-42.	1.2	17
74	Efficacy Outcomes in Patients Using Alefacept in the AWARE Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S122-S130.	1.2	2
75	Nail Psoriasis and Biologics. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 1-5.	1.2	18
76	Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S58-S66.	1.2	19
77	Are All Seborrheic Keratoses Benign? Review of the Typical Lesion and Its Variants. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008, 12, 203-210.	1.2	34
78	Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008, 12, 282-287.	1.2	0
79	Miliarial Gout (A New Entity). <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 31-34.	1.2	20
80	Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 1-27.	1.2	383
81	Use of Calcipotriene Cream (Dovonex?? Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex??). <i>American Journal of Clinical Dermatology</i> , 2006, 7, 177-184.	6.7	32
82	Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, 128-130.	1.2	14
83	Multitherapy Approach to Onychomycosis Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S44-S47.	1.2	8
84	Prevalence and Epidemiology of Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S28-S33.	1.2	28
85	Pharmacology of TNF inhibitors. , 2006, , 23-44.		8
86	Antihistamines in the Treatment of Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 467-473.	1.2	45